Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Free Cash Flow (2016 - 2025)

Avalo Therapeutics' Free Cash Flow history spans 12 years, with the latest figure at -$14.3 million for Q4 2025.

  • For Q4 2025, Free Cash Flow rose 5.03% year-over-year to -$14.3 million; the TTM value through Dec 2025 reached -$51.5 million, down 4.98%, while the annual FY2025 figure was -$51.5 million, 4.98% down from the prior year.
  • Free Cash Flow reached -$14.3 million in Q4 2025 per AVTX's latest filing, up from -$16.4 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $5.6 million in Q3 2022 to a low of -$19.2 million in Q2 2021.
  • Average Free Cash Flow over 5 years is -$11.5 million, with a median of -$12.0 million recorded in 2022.
  • Peak YoY movement for Free Cash Flow: surged 134.4% in 2022, then plummeted 443.89% in 2024.
  • A 5-year view of Free Cash Flow shows it stood at -$17.1 million in 2021, then surged by 76.97% to -$3.9 million in 2022, then grew by 29.8% to -$2.8 million in 2023, then tumbled by 443.89% to -$15.0 million in 2024, then increased by 5.03% to -$14.3 million in 2025.
  • Per Business Quant, the three most recent readings for AVTX's Free Cash Flow are -$14.3 million (Q4 2025), -$16.4 million (Q3 2025), and -$11.3 million (Q2 2025).